Phase 3
N=15
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Gastric Cancer
Bottom Line
View on ClinicalTrials.gov: NCT00941655 ↗Enrolled (actual)
15
Serious AEs
60.0%
Results posted
Jul 2013
Primary outcome: Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Oxaliplatin (Drug); Irinotecan (Drug); 5-Fluorouracil (Drug); Leucovorin (Drug); Gastrectomy and/or metastasectomy (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- National Cancer Institute (NCI)
- Primary completion
- Jul 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I |
19; 11; 11; 4; 14; 5 | — |
| PRIMARY Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm II |
17; 6; 10; 0; 0; 8 | — |
| SECONDARY Number of Participants With Serious and Non-Serious Adverse Events |
8; 5 | — |
| SECONDARY 12 Months Disease Free Survival (DFS) |
2; 0 | — |
| SECONDARY Gillys Stage Before and After Surgery |
0; 0; 1; 0; 0; 0 | — |
| SECONDARY Completeness of Cytoreduction (CCR) Score |
0; 0; 0; 2; 0; 0 | — |
| SECONDARY Median Blood Loss During Surgery |
650 | — |
| SECONDARY Median Hospital Stay After Initial Surgery |
17 | — |
| SECONDARY Median Duration of Cytoreduction Surgery and Heated Intraperitoneal Chemotherapy (HIPEC) |
10.1 | — |
| SECONDARY Quality of Life (QOL) Parameters Between the Two Study Groups |
— | — |
| SECONDARY Patterns of Disease Recurrence Between the Two Therapeutic Approaches and Their Clinical Implications |
— | — |
Summary
Background:
* Gastric (stomach) cancer is a rare cancer. In most cases, by the time it has been diagnosed it has spread to other organs in the body and the chance of a cure is very small. The standard treatment for gastric cancer is a combination of chemotherapy drugs.
* Researchers are interested in finding out if surgically removing all tumors before beginning chemotherapy for stomach cancer can slow or halt its spread better than giving chemotherapy alone.
Objectives:
- To determine whether tumor removal surgery followed by chemotherapy is more effective in treating gastric cancer than chemotherapy given alone.
Eligibility:
- Patients 18 years of age and older who have been diagnosed with gastric cancer.
Design:
* All patients will undergo an initial physical examination, blood tests, imaging scans, and a laparoscopy to determine the extent of the disease.
* Half of the participants will be assigned to have surgery first and then chemotherapy; the other half will be assigned to have chemotherapy alone.
* The surgery-plus-chemotherapy group will have major surgery to remove all tumors in the stomach and abdominal area, followed by a recovery time of up to 4 weeks. Chemotherapy will begin 6 to 8 weeks after surgery.
* The chemotherapy-only group will begin treatment within 2 weeks of laparoscopy.
* All patients will receive four chemotherapy drugs: 5-Fluorouracil, leucovorin, oxaliplatin, and irinotecan. The drugs are given intravenously over 2 days every 2 weeks (one cycle) for 12 cycles (about 6 months), either at the National Institutes of Health (NIH) Clinical Center or at home with a referring oncologist. Patients in the surgery group who have tumors in the peritoneum will receive an additional set of chemotherapy drugs in a separate treatment.
* During the chemotherapy cycles, patients will provide blood samples approximately once a week and will have physical examinations and scans on a regular basis.
* Patients will return to the NIH Clinical Center for follow-up visits about every 4 months for 2 years, then every 6 months for 3 years and yearly thereafter.
Eligibility Criteria
-INCLUSION CRITERIA:
- Histologically or cytologically confirmed gastric adenocarcinoma.
- Metastatic disease must be measurable by computed tomography (CT) and/or magnetic resonance imaging (MRI)
Or
There must be a history of positive peritoneal washings or carcinomatosis
- All disease should be deemed resectable to negative margins (NED) based on imaging studies.
Note: Patients with both pulmonary and peritoneal metastases will be enrolled at the discretion of the Principal Investigator.
- Esophageal invasion < 4cm that does not require thoracotomy (Seiwert II and III lesions).
- Hepatic metastases (unilateral or bilateral less than or equal to 5 lesions, less than or equal to 15 cm total diameter).
- Primary peritoneal metastases (small disease load less than or equal to P2 disease) without massive ascites or intestinal obstruction.
- Para-aortic lymph node metastases (stations 16 a1 and/or b2).
- Lung metastases (less than or equal to 3 unilateral/bilateral, 9 cm total diameter).
- Patients who present with both hepatic and peritoneal metastases must have no evidence of extensive para-aortic/retro-pancreatic lymph node metastases.
- Greater than or equal to 18 years of age.
- Must be able to understand and sign the Informed Consent Document.
- Clinical performance status of Eastern Cooperative Oncology Group (ECOG) less than or equal to 2.
- Life expectancy of greater than three months.
- Patients of both genders must be willing to practice birth control during and for four months after receiving chemotherapy.
- Hematology:
- Absolute neutrophil count greater than 1300/mm^3 without the support of Filgrastim.
- Platelet count greater than 75,000/mm^3.
- Hemoglobin greater than 8.0 g/dl.
- Chemistry:
- Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than or equal to 5 times the upper limit of normal. Except in the presence of obstructive liver metastases where ALT/AST may be up to 10 times the upper limit of normal.
- Serum creatinine less than or equal to 1.5 mg/dl unless the measured creatinine clearance is greater than 60 mL/min/1.73 m^2.
- Total bilirubin less than or equal to 2 mg/dl, except in the presence of obstructive metastases.
- Prothrombin time (PT) within 2 seconds of the upper limit of normal (International Normalized Ratio (INR) less than or equal to 1.8).
- No history of prior/other malignancies within the 2 years prior to enrollment with the exception of basal cell carcinoma.
EXCLUSION CRITERIA
- Prior treatment with 5-FU, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) (treatment with any of the components as separate regimens is allowable).
- Inability to tolerate any of the chemotherapeutic agents.
- Grade 2 or greater neuropathy.
- Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the chemotherapy on the fetus or infant.
- Active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system; myocardial infarction; cardiac arrhythmias; obstructive or restrictive pulmonary disease.
- Brain metastases or a history of brain metastases.
- Childs B or C cirrhosis or with evidence of severe portal hypertension by history, endoscopy, or radiologic studies.
- Weight less than 40 kg.
- Significant ascites, greater than 1000cc in the absence of peritoneal disease.
- History of congestive heart failure and/or an left ventricular ejection fraction (LVEF) less than 40%.
Note: Patients at increased risk for coronary artery disease or cardiac dysfunction (e.g., greater than 65yo, diabetes, history of hypertension, elevated low-density lipoprotein (LDL), first degree relative with coronary artery disease) will undergo full cardiac evaluation and will not be eligible if they demonstrate significant irreversible ischemia on stress thallium or an ejection fraction < 40%.
- Significant chronic obstructive pulmonary disease (COPD)
Data sourced from ClinicalTrials.gov (NCT00941655). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.